Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate

Author: Benzinga Newsdesk | May 07, 2025 06:03am
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $0.12 by 3025 percent. This is a 1488.89 percent increase over losses of $(0.27) per share from the same period last year.

Posted In: MCRB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist